Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarit Hovav

Psychiatry Omaha, NE Medical Doctor

NPI 1326489550 CMS profile 657490

4242 Farnam St, Ste 355, Omaha, NE 68131

Open in the dashboard

General payments

$306,949

433 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarit Hovav of Omaha, NE is reported in the CMS Open Payments database as having received $306,949 across 433 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $56,975 68
2024 General $66,033 71
2023 General $29,125 39
2022 General $23,532 35
2021 General $27,077 44
2019 General $104,208 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarit Hovav
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Sarit Hovav were reported at $56,975. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Sarit Hovav Psychiatry median Middle half National median
2019 $104,208 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $27,077 $143 $43–$576 $132
2022 $23,532 $153 $50–$590 $149
2023 $29,125 $170 $56–$651 $160
2024 $66,033 $179 $57–$673 $164
2025 $56,975 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $201,637 232 payments
  2. Allergan Inc. $87,259 139 payments
  3. Alkermes, Inc. $16,665 21 payments
  4. Tris Pharma Inc $259 6 payments
  5. ITI, Inc. $224 3 payments
  6. Merz North America, Inc. $194 1 payment
  7. Axsome Therapeutics, Inc. $170 7 payments
  8. Avanir Pharmaceuticals, Inc. $146 6 payments
  9. Teva Pharmaceuticals USA, Inc. $125 2 payments
  10. Lundbeck LLC $70 4 payments
  11. Other $200 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $278,496 92 payments
  2. Travel and Lodging $22,218 146 payments
  3. Food and Beverage $6,102 185 payments
  4. Education $133 10 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $144,664 165 payments
  2. VRAYLAR Neuroscience $143,771 197 payments
  3. ARISTADA INITIO $16,665 21 payments
  4. ARISTADA Cns $16,665 21 payments
  5. ARISTADA Cns $16,665 21 payments
  6. ARISTADA Cns $16,632 20 payments
  7. ARISTADA Cns $16,632 20 payments
  8. CAPLYTA $224 3 payments
  9. Auvelity $170 7 payments
  10. FETZIMA $149 1 payment
  11. Other $756 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record